U.S. tightens scrutiny of China-linked biotech deals and overseas life-sciences investment
Congress and the Trump Administration are tightening restrictions on Chinese involvement in U.S. biotechnology, pharmaceuticals, and related intellectual property. The effort spans multiple agencies—Treasury, the Pentagon, CFIUS, and the White House—and relies on a suite of tools including the Pentagon's Chinese Military Companies list, Treasury's September 2025 Foreign Entities of Concern rulemaking, and a February 2025 presidential memorandum directing CFIUS to block Chinese investment in sensitive health care sectors. The House Select Committee on the Chinese Communist Party has separately signaled support for restricting U.S. business funding of Chinese military-linked companies.